Persistent obesity since childhood or adolescence accelerates biological aging in young adults from Chile’s oldest birth cohort - Correa, mP; Burrows, R; Albala, C; Sepúlveda, C; Salech, F; Troncoso, R; Gonzalez-Billault, C (medRxiv, 2024)
Aging and obesity are primary risk factors for chronic conditions such as hypertension and diabetes. However, a mechanistic correlation between these risk factors has not been fully established. Using a historical birth cohort from Chile, we delve into the relationship between obesity and accelerated aging, spanning cellular to systemic levels. The cohort, comprising men and women in their late 20s, had their BMI recorded since birth, with 57% having obesity since childhood or adolescence. Our aim was to investigate if persistent obesity since childhood or adolescence leads to the display of molecular aging features in young adulthood. We also sought to determine whether cardiometabolic health issues accompanied this early aging phenotype. We used inferential statistics and data mining for analysis. Results show that persistent obesity since childhood or adolescence leads to epigenetic changes, telomere shortening, chronic inflammation, impaired nutrient sensing, mitochondrial stress, and diminished intercellular communication, resembling a compound network of interactions. This obesity-induced accelerated aging phenotype coincided with persistent decline of the cardiometabolic profile. Implications of our findings are significant and suggest that integrating molecular markers with clinical and epidemiological data could be valuable in identifying individuals at increased disease risk due to accelerated aging.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://bmcgeriatr.biomedcentral.com/articles/10.1186/s12877-022-03032-4 Funding StatementThis research was supported by grants from Agencia Nacional de Investigacion y Desarrollo (ANID) (Chile) through Anillos de Investigacion en Ciencia y Tecnologia (ACT210006 to PC, CA, RB, FS, RT, CGB); Fondo Nacional de Investigaciones Cientificas y Tecnologicas (FONDECYT #1210283 to RB, PC); Centro de Gerociencia, Salud Mental y Metabolismo (GERO) (FONDAP #15150012 to CGB, FC, FS). Fundacion MAPFRE (Spain) also provided support through Ayudas a la Investigacion Ignacio H. de Larramendi (MAPFRE-2101 to PC, CA, RB, FS, CGB). The funders had no role in study design, data collection and analysis, data interpretation, decision to publish or preparation of manuscripts from the ObAGE Study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRBs of the Institute of Nutrition and Food Technology, University of Chile, obtained ethical approval (resolution date: December 1, 2021; number: 21-037). According to the norms for human experimentation, informed and written consent will be obtained from all individual participants included in the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.BAZBMI for age and sexBMIBody mass indexCAgeChronological ageCIMTlCarotid intima-media thickness (left)CMITrCarotid intima-media thickness (right)DBPDiastolic blood pressureDNAmTLDNA methylation estimated telomere lengthDXADual-energy X-ray absorptiometryFGF21Fibroblast growth factor 21FMWhole body fat massGDF11Growth Differentiation Factor 11GDF15Growth Differentiation Factor 15GliFasting glycemiaHCAHierarchical clustering analysisHDLHigh-density lipoproteinHOMA-IRHomeostatic Model Assessment -Insulin ResistanceHOMA-βHomeostatic Model Assessment -β cell functionhs CRPHigh sensitivity C reactive proteinIL10Interleukin 10IL2Interleukin 2IL6Interleukin 6InsFasting insulinMetSMetabolic SyndromeNAFLDNon-alcoholic fatty liver diseaseNCDsNon-communicable chronic diseasesOCAObesity since childhood or adolescencePWVPulse wave velocitySBPSystolic blood pressureSPISESingle-point insulin sensitivity estimatorT2DType-2 diabetesTGFasting triglyceridesTNAαTumoral Necrosis Factor αVATVisceral adipose tissueWCWaist circumferenceWtHtRWaist-to-height ratio